

---

**Technical Brief**  
**September 5<sup>th</sup>, 2023**  
**Emerging SARS-CoV-2 Variants**  
**and Detection by the Lucira COVID-19 Check-It, All-In-One Test Kits and**  
**COVID-19 & Flu Test kit**

The Centers for Disease Control and Prevention (CDC)<sup>1</sup> and the World Health Organization (WHO)<sup>2</sup> have highlighted surveillance of the following lineages:

BA.2.75, BA.2.86, CH.1.1, EG.5, EG.6.1, FL.1.5.1, GE.1, HV.1, XBB, XBB.1.5, XBB.1.5.70, XBB.1.5.72, XBB.1.16, XBB.1.16.1, XBB.1.16.6, XBB.1.42, XBB.1.9.1, XBB.1.9.2, and XBB.2.3

Lucira Health by Pfizer performs routine surveillance of emerging SARS-CoV-2 strains by periodically evaluating *in silico* reactivity against sequence databases. These evaluations have shown that these lineages are reactive to the Lucira COVID-19 Check-It, All-In-One Test Kits and the Lucira COVID-19 & Flu Test kit. The Lucira Health assay targets two non-overlapping regions of the SARS-CoV-2 genome. The detection regions are unaffected by the mutations in the spike protein of SARS-CoV-2 in the variant strains.

Lucira Health will continue to monitor the situation with emerging variants of SARS-CoV-2.

If you have any questions on the above, please reach out to Technical Support at [techsupport@lucirahealth.com](mailto:techsupport@lucirahealth.com).

<sup>1</sup><https://covid.cdc.gov/covid-data-tracker/#variant-proportions>

<sup>2</sup><https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/>